Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Spero Therapeutics Q2 2024 GAAP EPS $(0.33) Beats $(0.38) Estimate, Sales $10.197M Beat $3.267M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:16pm
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 43.48 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $10.197 million which beat the analyst consensus estimate of $3.267 million by 212.15 percent. This is a 275.44 percent increase over sales of $2.716 million the same period last year.

Posted In: SPRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist